Advertisement

NONMEM Population Models of Cytosine Arabinoside and Fludarabine Phosphate in Pediatric Patients With Leukemia

  • Vassilios I. Avramis
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Computer software NONMEM for nonlinear mixed-effects modeling was used to determine the population pharmacokinetics (PPK) and pharmacodynamics (PPD) of intravenously administered nucleoside analogs cytosine arabinoside (ara-C) and fludarabine phosphate (F-ara-A) in pediatric patients with leukemias. A description of the major NONMEM tasks as well as the statistical models has been given for these drugs. Two pharmacokineticpharmacodynamic (PK-PD) models have been developed for ara-C and one for F-ara-A. These NONMEM population analyses present a novel approach for determining the PK parameters in many patients; these parameters are superimposable to the ones derived from the classical two-stage PK approach. However, by minimizing errors, population analyses explained the significant variabilities in the elimination of these drugs from the central compartment and the variable high peak plasma concentrations in younger leukemia patients. Moreover, the influence of the covariate product (TR AGE × SA) demonstrated an increase in the PK parameter values with increasing patient age (AGE) and surface area (SA). The evaluation of the intercompartmental clearance of ara-C demonstrated statistically significant linear relationships with the covariate product (AGE × SA). These results explained the lower drug plasma concentration in the older children as compared to the infant and younger patients with leukemias. In addition to the classical population pharmacokinetic and population pharmacodynamic parameters of half-lives of elimination, clearance, and volumes of distribution, these analyses in pediatric patients determined the effects of deamination by cytidine deaminase on the clearance of ara-C from the circulation. Moreover, the K m of activation of these drugs to their respective phosporylated anabolites in patients, and under treatment conditions, was determined by the Michaelis-Menten equation, which was fused into the INPUT PK-PD subroutine. Overall, NONMEM population PK-PD analyses are complicated and time consuming and require a rich database from many patients. However, they produce the best possible PK-PD analyses for a drug and its metabolites, the parameters of which give better understanding of the biochemical pathways in plasma and in leukemic blasts simultaneously, which can then be applied to many other patients in future clinical trials.

Key Words

Acute lymphoblastic leukemia, ALL apparent volume of distribution, Vd cytosine arabinoside, ara-C fludarabine phosphate, F-ara-A interindividual variance, ω2 nonlinear mixed-effects modeling, NONMEM total body clearance, CL value of minimum objective function, OBF vector of intraindividual effects, εij vector of random interindividual effects, ηi

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Periclou AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by contin uous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996;39:42–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507–523.PubMedGoogle Scholar
  3. 3.
    Ochs J, Sinkule JA, Danks MK, Look AT, Bowman WP, Rivera G. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. J Clin Oncol 1984;2:1092–1097.PubMedGoogle Scholar
  4. 4.
    Avramis VI, Biener R, Krailo M, et al. Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 1987; 47:6786–6792.PubMedGoogle Scholar
  5. 5.
    Avramis VI, Weinberg KI, Sato JK, et al. Pharmacology studies of 1-β-D-arabi-nofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 1989;49:241–247.PubMedGoogle Scholar
  6. 6.
    Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children’s Cancer Group. J Clin Oncol 1997;15:2780–2785.PubMedGoogle Scholar
  7. 7.
    Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-β-D-arabino-furanosyl-2-fluoroadenine (F-araA) against murine leukemia P388. Cancer Res 1982;42:2587–2596.PubMedGoogle Scholar
  8. 8.
    Momparler RL. A model for the chemotherapy of acute leukemia with 1-β-D-ara-binofuranosylcytosine. Cancer Res 1974;34:1775–1787.PubMedGoogle Scholar
  9. 9.
    Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986;4:1079–1088.PubMedGoogle Scholar
  10. 10.
    Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabi-nosylnucleotides in human leukemia cells. Cancer Res 1988;48:329–334. 11.PubMedGoogle Scholar
  11. 11.
    Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children’s Cancer Group. Clin Cancer Res 1998; 1:45–52.Google Scholar
  12. 12.
    Avramis VI, Champange J, Sato J, et al. Pharmacology and phase I/II trial of fludarabine as a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990;50:7226–7231.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Vassilios I. Avramis
    • 1
    • 2
  1. 1.Keck School of MedicineUniversity of Southern CaliforniaUSA
  2. 2.Department of Pediatrics, Division of Hematology/OncologyChildrens Hospital Los AngelesLos AngelesUSA

Personalised recommendations